NCT00094055

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.

Conditions

• Thyroid Neoplasms

Interventions

Type	Name	Description
DRUG	AG013736	AG013736, tablets 5 mg BID daily until tumor progression or toxicity

Timeline

• Start date: 2004-09-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2004-10-11
• Last updated: 2012-06-26
• Results posted: 2012-03-30

Locations

9 sites across 1 country: United States